Ahva Shahabi1, Raj Satkunasivam2, Inderbir S Gill2, Gary Lieskovsky2, Sia Daneshmand2, Jacek K Pinski3, Mariana C Stern1. 1. Department of Preventive Medicine, Keck School of Medicine of USC; 2. Department of Urology, USC Institute of Urology and Norris Comprehensive Cancer Center, Keck School of Medicine of USC; 3. Department of Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, CA, U.S.A.
Abstract
INTRODUCTION: We sought to determine predictors for early and late biochemical recurrence following radical prostatectomy among localized prostate cancer patients. METHODS: The study included localized prostate cancer patients treated with radical prostatectomy (RP) at the University of Southern California from 1988 to 2008. Competing risks regression models were used to determine risk factors associated with earlier or late biochemical recurrence, defined using the median time to biochemical recurrence in this population (2.9 years after radical prostatectomy). RESULTS: The cohort for this study included 2262 localized prostate cancer (pT2-3N0M0) patients who did not receive neoadjuvant or adjuvant therapies. Of these patients, 188 experienced biochemical recurrence and a subset continued to clinical recurrence, either within (n=19, 10%) or following (n=13, 7%) 2.9 years after RP. Multivariable stepwise competing risks analysis showed Gleason score ≥7, positive surgical margin status, and ≥pT3a stage to be associated with biochemical recurrence within 2.9 years following surgery. Predictors of biochemical recurrence after 2.9 years were Gleason score 7 (4+3), preoperative prostate-specific antigen (PSA) level, and ≥pT3a stage. CONCLUSIONS: Higher stage was associated with biochemical recurrence at any time following radical prostatectomy. Particular attention may need to be made to patients with stage ≥pT3a, higher preoperative PSA, and Gleason 7 prostate cancer with primary high-grade patterns when considering longer followup after RP.
INTRODUCTION: We sought to determine predictors for early and late biochemical recurrence following radical prostatectomy among localized prostate cancerpatients. METHODS: The study included localized prostate cancerpatients treated with radical prostatectomy (RP) at the University of Southern California from 1988 to 2008. Competing risks regression models were used to determine risk factors associated with earlier or late biochemical recurrence, defined using the median time to biochemical recurrence in this population (2.9 years after radical prostatectomy). RESULTS: The cohort for this study included 2262 localized prostate cancer (pT2-3N0M0) patients who did not receive neoadjuvant or adjuvant therapies. Of these patients, 188 experienced biochemical recurrence and a subset continued to clinical recurrence, either within (n=19, 10%) or following (n=13, 7%) 2.9 years after RP. Multivariable stepwise competing risks analysis showed Gleason score ≥7, positive surgical margin status, and ≥pT3a stage to be associated with biochemical recurrence within 2.9 years following surgery. Predictors of biochemical recurrence after 2.9 years were Gleason score 7 (4+3), preoperative prostate-specific antigen (PSA) level, and ≥pT3a stage. CONCLUSIONS: Higher stage was associated with biochemical recurrence at any time following radical prostatectomy. Particular attention may need to be made to patients with stage ≥pT3a, higher preoperative PSA, and Gleason 7 prostate cancer with primary high-grade patterns when considering longer followup after RP.
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Jens Hansen; Marco Bianchi; Maxine Sun; Michael Rink; Fabio Castiglione; Firas Abdollah; Thomas Steuber; Sascha A Ahyai; Stefan Steurer; Cosima Göbel; Massimo Freschi; Francesco Montorsi; Shahrokh F Shariat; Margit Fisch; Markus Graefen; Pierre I Karakiewicz; Alberto Briganti; Felix K-H Chun Journal: BJU Int Date: 2013-12-02 Impact factor: 5.588
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Alan W Partin Journal: J Urol Date: 2006-10 Impact factor: 7.450
Authors: Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Jochen Walz; Felix K-H Chun; Eric A Klein; Alwyn Reuther; Fred Saad; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz Journal: J Urol Date: 2008-12-13 Impact factor: 7.450
Authors: Arthur A Caire; Leon Sun; Oludotun Ode; Danielle A Stackhouse; Kelly Maloney; Craig Donatucci; Vladimir Mouraviev; Thomas J Polascik; Cary N Robertson; David M Albala; Judd W Moul Journal: Urology Date: 2009-06-07 Impact factor: 2.649
Authors: Dimple Chakravarty; Parita Ratnani; Li Huang; Zachary Dovey; Stanislaw Sobotka; Roy Berryhill; Harri Merisaari; Majd Al Shaarani; Richa Rai; Ivan Jambor; Kamlesh K Yadav; Sandeep Mittan; Sneha Parekh; Julia Kodysh; Vinayak Wagaskar; Rachel Brody; Carlos Cordon-Cardo; Dmitry Rykunov; Boris Reva; Elai Davicioni; Peter Wiklund; Nina Bhardwaj; Sujit S Nair; Ashutosh K Tewari Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575